The Atherosclerosis Market Economic Outlook is a paradox of high financial burden and profound cost-effectiveness potential, shaping the decisions of policymakers and payers globally. The core economic challenge stems from the substantial, direct healthcare costs associated with treating the acute consequences of atherosclerosis, primarily myocardial infarction (MI) and stroke, which require expensive emergency room visits, prolonged hospitalization, intensive care, and costly revascularization procedures (PCI or CABG). This acute care expenditure is the primary financial driver of the disease, ensuring that the market for both acute and chronic care remains recession-proof and large.

However, the optimistic long-term economic outlook is predicated on the proven concept that prevention is vastly more cost-effective than treatment. The widespread use of low-cost generic drugs like statins and aspirin is one of the greatest public health cost savings in modern medicine. The economic debate now focuses on integrating high-cost, novel therapies into this existing cost-saving model. While the initial price of new biologics (e.g., PCSK9 inhibitors) and RNA-based drugs is high, their superior efficacy in high-risk groups, by significantly reducing the rate of future MIs and strokes, is the key argument for their overall long-term cost-effectiveness. The future economic health of the market depends on payers’ willingness to cover these premium treatments based on favorable Health Economics and Outcomes Research (HEOR) data. As global healthcare systems shift towards value-based care models, the economic outlook favors manufacturers who can demonstrate that their products, despite their high cost, substantially reduce the financial and human toll of catastrophic cardiovascular events, ultimately translating better patient outcomes into favorable market economics.